Bates JE, et al. - Investigators assessed 27 subjects with 60 primarily metachronous metastases to analyze consequences after stereotactic ablative body radiotherapy for oligometastatic (1-5 metastatic foci) head-and-neck squamous cell carcinoma (OM-HNSCC) between 2012 and 2016. They noticed that 44.4% of cases had solitary, 44.4% had 2-3, and 11.1% had >3 metastases with the highest incidence of metastases in the lung (44 of 60 metastases). They recorded a median overall survival (OS) of 1.9 years. At 1 and 2 years, 78% and 43% of candidates were recorded alive (14% without disease progression). Overall, they suggested good OS and poor disease-free survival.